Ironwood(US:IRWD) Businesswire·2025-11-10 12:05Core Insights - Ironwood Pharmaceuticals reported strong third-quarter results for 2025, with significant growth in LINZESS sales and raised financial guidance for the full year [1][2][20] - The FDA approved LINZESS for treating children aged 7 years and older with irritable bowel syndrome with constipation (IBS-C), expanding its market potential [1][3] Financial Performance - U.S. net sales of LINZESS reached $315 million in Q3 2025, a 40% increase year-over-year [1][10] - Total revenue for Q3 2025 was $122.1 million, compared to $91.6 million in Q3 2024 [14] - GAAP net income was $40 million, or $0.25 per share (basic), compared to $3.6 million, or $0.02 per share (basic) in Q3 2024 [4][19] - Adjusted EBITDA for Q3 2025 was $81.8 million, up from $34.5 million in Q3 2024 [19] Guidance and Expectations - The company raised its full-year 2025 guidance for LINZESS U.S. net sales to $860 - $890 million, total revenue to $290 - $310 million, and adjusted EBITDA to greater than $135 million [1][20] - Ironwood anticipates continued strong LINZESS prescription demand growth in Q4 2025, although it expects reduced net pricing due to gross-to-net rebate reserves [20] Strategic Developments - Ironwood is advancing the apraglutide program towards a Phase 3 trial, with plans to align on trial design with the FDA later this year [3][11] - The company is reviewing strategic alternatives to maximize shareholder value and is engaged in settlement negotiations regarding litigation with Ferring International Center S.A. [17][3] Market Dynamics - LINZESS prescription demand in Q3 2025 was 60.5 million capsules, a 12% increase compared to Q3 2024 [11] - The commercial margin for LINZESS was 76% in Q3 2025, up from 65% in Q3 2024 [9]